<DOC>
	<DOCNO>NCT02936999</DOCNO>
	<brief_summary>The purpose study determine safety usefulness oral Vitamin D supplementation subject situ carcinoma . More specifically , study do ( 1 ) understand effect Vitamin D supplementation behavior breast cancer cell ( 2 ) development invasive breast cancer disease .</brief_summary>
	<brief_title>Vitamin D Supplementation Women With DCIS and/or LCIS</brief_title>
	<detailed_description>In vitro , calcitriol , potent metabolite vitamin D , inhibit variety cellular pathway promote cell proliferation survival . Vitamin D show reduce growth breast cancer precursor cell cell culture study . In animal model Vitamin D show prevent growth progression transplant cell line MCF710A , model pre-invasive cancer . Serum Vitamin D level deficiency correlate increase risk breast cancer , reduce survival breast cancer patient . Vitamin D also recognize effect immune cell function autoimmunity . The safety profile oral Vitamin D , metabolite calcitriol , well establish moderate term acute therapy worldwide . Potential additional primary secondary benefit vitamin D ) suppression carcinogen-induced transformation progression breast epithelium , b ) enhancement innate immune defense pre-invasive breast cancer lesion , c ) qualification combination therapy combine neoadjuvant therapy DCIS . Patients diagnose core biopsy carcinoma situ , ductal lobular , evaluate vitamin supplementation . Patients vitamin level less 50 eligible participation . They receive one month ( 30 day ) schedule vitamin D supplementation proceed standard care surgical excision . Immunohistochemistry study perform diagnostic core biopsy surgical specimen evaluate impact vitamin supplementation : proliferative index-ki67 , proliferative marker- PCNA , proteins autophagy pathway ( LC3B , ATG7 ) , her2 localization , level PMCA2 - calcium efflux channel .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Subjects must tissue diagnosis lobular carcinoma situ ductal carcinoma situ schedule undergo excision cancer Subjects must female least 18 year age Subjects must sign consent Normal liver function base ( total bilirubin AST &lt; 1.5 x Upper Limit Normal ) Serum creatinine &lt; 2.0 mg/dL Serum 25 ( OH ) D level &lt; 50 ng/ml Calcium within normal range ( 8.510.2 mg/dL ) ECOG performance status 02 Are able swallow retain oral medication Subjects willing abstain use hormonal therapy ( e.g . hormone replacement therapy , oral contraceptive pill , hormonecontaining IUDs , Estring ) Patient desire participate study Inability give consent Current use hormonecontaining form birth control implant ( i.e . Norplants , injectables ( i.e . depoprovera ) Currently lactate Patients history renal hepatic insufficiency Used investigational drug within 30 day 5 halflives , whichever longer , precede first dose study medication History granulomatous disease tuberculosis sarcoidosis History Vitamin D supplementation &gt; 2000 IU/day within last 2 month History hypoparathyroidism</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>